Oncolytic adenovirus compositions
AssigneeThe Salk Institute for Biological Studies
InventorsClodagh O'Shea, Shigeki Miyake-Stoner
Life of this patent
Estimating the term…
Abstract
An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications.
Claims10
A method of inducing cytotoxicity in an Rb-deficient tumor cell in a tumor comprising contacting the tumor cell with a recombinant adenovirus by local administration of the recombinant adenovirus to the tumor, wherein the recombinant adenovirus comprises a genome comprising:
- (i) an adenovirus E1A promoter operably linked to a nucleic acid sequence encoding an E1A protein comprising a modification in a first Rb-binding site;
- and
- (ii) an adenovirus E4 promoter operably linked to an E4orf6/7 gene product coding sequence comprising a deletion or modification of at least one of the two E4orf6/7 exons, wherein the deletion or the modification impairs E4orf6/7 gene product activity and/or expression,
- wherein the recombinant adenovirus induces cytotoxicity in the Rb-deficient tumor cell in the tumor.
Dependencies are inferred from the claim text.